Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afimoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 14/20 | 1.00 |
| ▸ | ESRRG known ✓ | P62508 | 8/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ESRRB | O95718 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 1.00 |
| ▸ | PLD1 | Q13393 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15668666 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL2132301 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL640496 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL2165503 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL11899365 | 0.99 | ESR1 (0.97) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL9121934 | 0.97 | ESR1 (0.95) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649806 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649812 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL9857240 | 0.95 | ESR1 (0.90) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL1056785 | 0.95 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26473 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122005516-A | Construction method and application of animal model of self-onset systemic lupus erythematosus | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2026-05-12 | — | — | CN | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20260118337-A1 | QUANTITATION OF TAMOXIFEN AND METABOLITES THEREOF BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260103758-A1 | METHODS AND BIOMARKERS FOR TREATING BREAST CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2026-04-16 | — | — | US | claimed |
| EP-4719405-A1 | METHODS AND MODIFIED DOSING REGIMENS COMPRISING A CDK4 INHIBITOR FOR THE TREATMENT OF CANCER | Pfizer Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260083859-A1 | SUSTAINED TRANSGENE EXPRESSION OF MODIFIED ERT2 PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES | SENTI BIOSCIENCES INC (US) | 2026-03-26 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| CN-121575044-A | Method for preparing congenital megacolon animal model by over-expressing Fut8 gene and application thereof | 广州医科大学附属妇女儿童医疗中心 | 2026-02-27 | — | — | CN | claimed |
| EP-0246654-B1 | Use of a sulfated polysaccharide | DAIICHI SEIYAKU CO (JP) | 1993-11-10 | — | — | EP | claimed |
| EP-0547141-A1 | ONSET OF ANTIESTROGEN RESISTANCE IN BREAST CANCER | THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-23 | — | — | EP | claimed |
| EP-0287690-B1 | STABLE SOLVENT ADDUCTS OF Z-1-(P-BETA-DIMETHYLAMINO-ETHOXYPHENYL)-1-(P-HYDROXYPHENYL)-2-PHENYLBUT-1-ENE | HEUMANN PHARMA GMBH & CO (DE) | 1992-09-02 | — | — | EP | claimed |
| US-5119827-A | An increase in ratio of cis-4-hydroxy-tamoxifen to trans form causes treatment resistance | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-06-09 | — | — | US | claimed |
| WO-1992003973-A1 | ONSET OF ANTIESTROGEN RESISTANCE IN BREAST CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-03-19 | — | — | WO | claimed |
| US-4973755-A | ANTIESTROGENS | HEUMANN PHARMA GMBH & CO. (DE) | 1990-11-27 | — | — | US | claimed |
| US-4900815-A | Sulfated polysaccharide DS4152 | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-02-13 | — | — | US | claimed |
| EP-0287690-A1 | Stable solvent adducts of Z-1-(p-beta-dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-ene | HEUMANN PHARMA GMBH & CO (DE) | 1988-10-26 | — | — | EP | claimed |
| EP-0246654-A2 | Use of a sulfated polysaccharide | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1987-11-25 | — | — | EP | claimed |
| US-4206234-A | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-06-03 | — | — | US | claimed |